Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention  Susan G. Komen for the Cure-AACR Outstanding Investigator Award for Breast Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation

[Cancer Research 57, 229-233, January 15, 1997]
© 1997 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Haldar, S.
Right arrow Articles by Croce, C. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Haldar, S.
Right arrow Articles by Croce, C. M.

Bcl2 Is the Guardian of Microtubule Integrity1

Subrata Haldar2, Aruna Basu and Carlo M. Croce

Kimmel Cancer Center, Jefferson Medical College, Philadelphia, Pennsylvania 19107

We have investigated the ability of several drugs commonly used in the treatment of human cancer to induce bcl2 phosphorylation and cell death in human cell lines derived from acute leukemia, lymphoma, breast cancer, and prostate cancer. The results of this analysis indicate that drugs affecting the integrity of microtubules induce bcl2 phosphorylation, whereas anticancer drugs damaging DNA do not. Comparison of the effects of taxol and its analogue, taxotere, indicates that taxotere is capable of inducing bcl2 phosphorylation and apoptotic cell death at 100-fold lower concentrations than taxol. Induction of cancer cell death through phosphorylation of bcl2 thus provides an opportunity not only for more refined targeting of therapeutic drugs but for understanding of an important pathway leading to apoptosis.

Phosphorylation of bcl2 in drug-treated cancer cells occurs in G2-M, the phase of the cell cycle in which this class of drugs is active. No induction of bcl2 phosphorylation occurs in chronic lymphocytic leukemia cells that overexpress bcl2 but are blocked at G0-G1. Thus, prevention of polymerization or depolymerization of cellular microtubules by this class of cancer therapeutic drugs causes phosphorylation of bcl2, abrogating the normal antiapoptotic function of bcl2 and initiating the apoptotic program in the cycling cancer cells; these results are consistent with a normal physiological role of bcl2 as "guardian of microtubule integrity."

1 Supported by the Council for Tobacco Research Grant 3496A (to S. H.) and National Cancer Institute Grant CA39860 (to C. M. C.).

2 To whom requests for reprints should be addressed, at Kimmel Cancer Center, Bluemle Life Sciences Building, Rm. 1032, 233 South 10th Street, Philadelphia, PA 19107-5799.

Received 12/ 2/96. Accepted 12/23/96.




This article has been cited by other articles:


Home page
JCOHome page
N. J. Sanfilippo, S. S. Taneja, A. Chachoua, H. Lepor, and S. C. Formenti
Phase I/II Study of Biweekly Paclitaxel and Radiation in Androgen-Ablated Locally Advanced Prostate Cancer
J. Clin. Oncol., June 20, 2008; 26(18): 2973 - 2978.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
S. L. Mooberry, K. N. Weiderhold, S. Dakshanamurthy, E. Hamel, E. J. Banner, A. Kharlamova, J. Hempel, J. T. Gupton, and M. L. Brown
Identification and Characterization of a New Tubulin-Binding Tetrasubstituted Brominated Pyrrole
Mol. Pharmacol., July 1, 2007; 72(1): 132 - 140.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. N. Shajahan, A. Wang, M. Decker, R. D. Minshall, M. C. Liu, and R. Clarke
Caveolin-1 Tyrosine Phosphorylation Enhances Paclitaxel-mediated Cytotoxicity
J. Biol. Chem., February 23, 2007; 282(8): 5934 - 5943.
[Abstract] [Full Text] [PDF]


Home page
Jpn J Clin OncolHome page
Y.-C. Lin, H.-K. Chang, J.-S. Chen, H.-M. Wang, T.-S. Yang, and C.-C. Liaw
A Phase II Randomized Study of Two Taxanes and Cisplatin for Metastatic Breast Cancer after Anthracycline: A Final Analysis
Jpn. J. Clin. Oncol., January 1, 2007; 37(1): 23 - 29.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
M.-A. Esteve, M. Carre, V. Bourgarel-Rey, A. Kruczynski, G. Raspaglio, C. Ferlini, and D. Braguer
Bcl-2 down-regulation and tubulin subtype composition are involved in resistance of ovarian cancer cells to vinflunine.
Mol. Cancer Ther., November 1, 2006; 5(11): 2824 - 2833.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
T. Yoshino, H. Shiina, S. Urakami, N. Kikuno, T. Yoneda, K. Shigeno, and M. Igawa
Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy.
Clin. Cancer Res., October 15, 2006; 12(20): 6116 - 6124.
[Abstract] [Full Text] [PDF]


Home page
Biol Res NursHome page
L. J. Wood, L. M. Nail, N. A. Perrin, C. R. Elsea, A. Fischer, and B. J. Druker
The Cancer Chemotherapy Drug Etoposide (VP-16) Induces Proinflammatory Cytokine Production and Sickness Behavior-like Symptoms in a Mouse Model of Cancer Chemotherapy-Related Symptoms.
Biol Res Nurs, October 1, 2006; 8(2): 157 - 169.
[Abstract] [PDF]


Home page
JCOHome page
A. D. Colevas
Chemotherapy Options for Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
J. Clin. Oncol., June 10, 2006; 24(17): 2644 - 2652.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Cell Mol. Bio.Home page
Y. Tesfaigzi
Roles of Apoptosis in Airway Epithelia
Am. J. Respir. Cell Mol. Biol., May 1, 2006; 34(5): 537 - 547.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
W. A. Messersmith, S. D. Baker, L. Lassiter, R. A. Sullivan, K. Dinh, V. I. Almuete, J. J. Wright, R. C. Donehower, M. A. Carducci, and D. K. Armstrong
Phase I Trial of Bortezomib in Combination with Docetaxel in Patients with Advanced Solid Tumors
Clin. Cancer Res., February 15, 2006; 12(4): 1270 - 1275.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
D. L. Morse, H. Gray, C. M. Payne, and R. J. Gillies
Docetaxel induces cell death through mitotic catastrophe in human breast cancer cells
Mol. Cancer Ther., October 1, 2005; 4(10): 1495 - 1504.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. Tabuchi, H. To, H. Sakaguchi, N. Goto, A. Takeuchi, S. Higuchi, and S. Ohdo
Therapeutic Index by Combination of Adriamycin and Docetaxel Depends on Dosing Time in Mice
Cancer Res., September 15, 2005; 65(18): 8448 - 8454.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
S.E. Jones, J. Erban, B. Overmoyer, G.T. Budd, L. Hutchins, E. Lower, L. Laufman, S. Sundaram, W.J. Urba, K.I. Pritchard, et al.
Randomized Phase III Study of Docetaxel Compared With Paclitaxel in Metastatic Breast Cancer
J. Clin. Oncol., August 20, 2005; 23(24): 5542 - 5551.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
L A Emens, R T Reilly, and E M Jaffee
Breast cancer vaccines: maximizing cancer treatment by tapping into host immunity
Endocr. Relat. Cancer, March 1, 2005; 12(1): 1 - 17.
[Abstract] [Full Text] [PDF]


Home page
Jpn J Clin OncolHome page
S. Takahashi, M. Suzuki, H. Kume, S. Matsumoto, N. Okamoto, H. Nishimatsu, K. Tomita, and T. Kitamura
Combination Chemotherapy of Docetaxel, Ifosfamide and Cisplatin (DIP) in Patients with Metastatic Urothelial Cancer: a Preliminary Report
Jpn. J. Clin. Oncol., February 1, 2005; 35(2): 79 - 83.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
B. Gu, L. Espana, O. Mendez, A. Torregrosa, and A. Sierra
Organ-selective chemoresistance in metastasis from human breast cancer cells: inhibition of apoptosis, genetic variability and microenvironment at the metastatic focus
Carcinogenesis, December 1, 2004; 25(12): 2293 - 2301.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
B. Pourroy, M. Carre, S. Honore, V. Bourgarel-Rey, A. Kruczynski, C. Briand, and D. Braguer
Low Concentrations of Vinflunine Induce Apoptosis in Human SK-N-SH Neuroblastoma Cells through a Postmitotic G1 Arrest and a Mitochondrial Pathway
Mol. Pharmacol., September 1, 2004; 66(3): 580 - 591.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
G. Kuznetsov, M. J. Towle, H. Cheng, T. Kawamura, K. TenDyke, D. Liu, Y. Kishi, M. J. Yu, and B. A. Littlefield
Induction of Morphological and Biochemical Apoptosis following Prolonged Mitotic Blockage by Halichondrin B Macrocyclic Ketone Analog E7389
Cancer Res., August 15, 2004; 64(16): 5760 - 5766.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
J. Marshall, H. Chen, D. Yang, M. Figueira, K. B. Bouker, Y. Ling, M. Lippman, S. R. Frankel, and D. F. Hayes
A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors
Ann. Onc., August 1, 2004; 15(8): 1274 - 1283.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
W. L. Dahut, J. L. Gulley, P. M. Arlen, Y. Liu, K. M. Fedenko, S. M. Steinberg, J. J. Wright, H. Parnes, C. C. Chen, E. Jones, et al.
Randomized Phase II Trial of Docetaxel Plus Thalidomide in Androgen-Independent Prostate Cancer
J. Clin. Oncol., July 1, 2004; 22(13): 2532 - 2539.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C.-C. Kuo, H.-P. Hsieh, W.-Y. Pan, C.-P. Chen, J.-P. Liou, S.-J. Lee, Y.-L. Chang, L.-T. Chen, C.-T. Chen, and J.-Y. Chang
BPR0L075, a Novel Synthetic Indole Compound with Antimitotic Activity in Human Cancer Cells, Exerts Effective Antitumoral Activity in Vivo
Cancer Res., July 1, 2004; 64(13): 4621 - 4628.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
J. Gligorov and J. P. Lotz
Preclinical Pharmacology of the Taxanes: Implications of the Differences
Oncologist, June 2, 2004; 9(suppl_2): 3 - 8.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
M. D. Pegram, G. E. Konecny, C. O'Callaghan, M. Beryt, R. Pietras, and D. J. Slamon
Rational Combinations of Trastuzumab With Chemotherapeutic Drugs Used in the Treatment of Breast Cancer
J Natl Cancer Inst, May 19, 2004; 96(10): 739 - 749.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
H. To, M. Shin, M. Tabuchi, H. Sakaguchi, A. Takeuchi, N. Matsunaga, S. Higuchi, and S. Ohdo
Influence of Dosing Schedule on Toxicity and Antitumor Effects of a Combination of Adriamycin and Docetaxel in Mice
Clin. Cancer Res., January 15, 2004; 10(2): 762 - 769.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
A. Masuda, K. Maeno, T. Nakagawa, H. Saito, and T. Takahashi
Association between Mitotic Spindle Checkpoint Impairment and Susceptibility to the Induction of Apoptosis by Anti-Microtubule Agents in Human Lung Cancers
Am. J. Pathol., September 1, 2003; 163(3): 1109 - 1116.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
T. L. Tinley, D. A. Randall-Hlubek, R. M. Leal, E. M. Jackson, J. W. Cessac, J. C. Quada Jr., T. K. Hemscheidt, and S. L. Mooberry
Taccalonolides E and A: Plant-derived Steroids with Microtubule-stabilizing Activity
Cancer Res., June 15, 2003; 63(12): 3211 - 3220.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
M. Motwani, C. Rizzo, F. Sirotnak, Y. She, and G. K. Schwartz
Flavopiridol Enhances the Effect of Docetaxel in Vitro and in Vivo in Human Gastric Cancer Cells
Mol. Cancer Ther., June 1, 2003; 2(6): 549 - 555.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
K. Shimada, M. Nakamura, E. Ishida, M. Kishi, and N. Konishi
Roles of p38- and c-jun NH2-terminal kinase-mediated pathways in 2-methoxyestradiol-induced p53 induction and apoptosis
Carcinogenesis, June 1, 2003; 24(6): 1067 - 1075.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
T. L. Tinley, R. M. Leal, D. A. Randall-Hlubek, J. W. Cessac, L. R. Wilkens, P. N. Rao, and S. L. Mooberry
Novel 2-Methoxyestradiol Analogues with Antitumor Activity
Cancer Res., April 1, 2003; 63(7): 1538 - 1549.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
R. Danesi, F. De Braud, S. Fogli, T. M. De Pas, A. Di Paolo, G. Curigliano, and M. Del Tacca
Pharmacogenetics of Anticancer Drug Sensitivity in Non-Small Cell Lung Cancer
Pharmacol. Rev., March 1, 2003; 55(1): 57 - 103.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
A. J. van de Wouw, R. L. H. Jansen, E. J. M. Speel, and H. F. P. Hillen
The unknown biology of the unknown primary tumour: a literature review
Ann. Onc., February 1, 2003; 14(2): 191 - 196.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
F. Ravandi, M. Talpaz, and Z. Estrov
Modulation of Cellular Signaling Pathways: Prospects for Targeted Therapy in Hematological Malignancies
Clin. Cancer Res., February 1, 2003; 9(2): 535 - 550.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
G. H. Yoo, M. P. Piechocki, J. F. Ensley, T. Nguyen, J. Oliver, H. Meng, D. Kewson, T. Y. Shibuya, F. Lonardo, and M. A. Tainsky
Docetaxel Induced Gene Expression Patterns in Head and Neck Squamous Cell Carcinoma Using cDNA Microarray and PowerBlot
Clin. Cancer Res., December 1, 2002; 8(12): 3910 - 3921.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
J.-i. Sasaki, R. Ramesh, S. Chada, Y. Gomyo, J. A. Roth, and T. Mukhopadhyay
The Anthelmintic Drug Mebendazole Induces Mitotic Arrest and Apoptosis by Depolymerizing Tubulin in Non-Small Cell Lung Cancer Cells
Mol. Cancer Ther., November 1, 2002; 1(13): 1201 - 1209.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
H. Ben-Bassat, Z. Hartzstark, R. Levitzki, B. Y. Klein, Z. Shlomai, A. Gazit, and A. Levitzki
Tyrosine Kinase Inhibitors Suppress the Growth of Non-Hodgkin B Lymphomas
J. Pharmacol. Exp. Ther., October 1, 2002; 303(1): 163 - 171.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. Mabuchi, M. Ohmichi, A. Kimura, K. Hisamoto, J. Hayakawa, Y. Nishio, K. Adachi, K. Takahashi, E. Arimoto-Ishida, Y. Nakatsuji, et al.
Inhibition of Phosphorylation of BAD and Raf-1 by Akt Sensitizes Human Ovarian Cancer Cells to Paclitaxel
J. Biol. Chem., August 30, 2002; 277(36): 33490 - 33500.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
Y. Kaluzhny, G. Yu, S. Sun, P. A. Toselli, B. Nieswandt, C. W. Jackson, and K. Ravid
BclxL overexpression in megakaryocytes leads to impaired platelet fragmentation
Blood, August 13, 2002; 100(5): 1670 - 1678.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
P. A. Burke, S. J. DeNardo, L. A. Miers, K. R. Lamborn, S. Matzku, and G. L. DeNardo
Cilengitide Targeting of {alpha}v{beta}3 Integrin Receptor Synergizes with Radioimmunotherapy to Increase Efficacy and Apoptosis in Breast Cancer Xenografts
Cancer Res., August 1, 2002; 62(15): 4263 - 4272.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
S. Goodin, K. V. Rao, and R. S. DiPaola
State-of-the-Art Treatment of Metastatic Hormone-Refractory Prostate Cancer
Oncologist, August 1, 2002; 7(4): 360 - 370.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. P. Piechocki, F. Lonardo, J. F. Ensley, T. Nguyen, H. Kim, and G. H. Yoo
Anticancer Activity of Docetaxel in Murine Salivary Gland Carcinoma
Clin. Cancer Res., March 1, 2002; 8(3): 870 - 877.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. F. Kidd, M. F. Pilkington, M. J. Schell, K. E. Fogarty, J. N. Skepper, C. W. Taylor, and P. Thorn
Paclitaxel Affects Cytosolic Calcium Signals by Opening the Mitochondrial Permeability Transition Pore
J. Biol. Chem., February 15, 2002; 277(8): 6504 - 6510.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
C. Paul, F. Manero, S. Gonin, C. Kretz-Remy, S. Virot, and A.-P. Arrigo
Hsp27 as a Negative Regulator of Cytochrome c Release
Mol. Cell. Biol., February 1, 2002; 22(3): 816 - 834.
[Abstract] [Full Text] [PDF]


Home page
Arch Otolaryngol Head Neck SurgHome page
S. C. Coleman, Z. A. Stewart, T. A. Day, J. L. Netterville, B. B. Burkey, and J. A. Pietenpol
Analysis of Cell-Cycle Checkpoint Pathways in Head and Neck Cancer Cell Lines: Implications for Therapeutic Strategies
Arch Otolaryngol Head Neck Surg, February 1, 2002; 128(2): 167 - 176.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. Konopleva, T. Tsao, P. Ruvolo, I. Stiouf, Z. Estrov, C. E. Leysath, S. Zhao, D. Harris, S. Chang, C. E. Jackson, et al.
Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia
Blood, January 1, 2002; 99(1): 326 - 335.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
S. A. Holstein and R. J. Hohl
Synergistic Interaction of Lovastatin and Paclitaxel in Human Cancer Cells
Mol. Cancer Ther., December 1, 2001; 1(2): 141 - 149.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
K. N. Chi, M. E. Gleave, R. Klasa, N. Murray, C. Bryce, D. E. Lopes de Menezes, S. D'Aloisio, and A. W. Tolcher
A Phase I Dose-finding Study of Combined Treatment with an Antisense Bcl-2 Oligonucleotide (Genasense) and Mitoxantrone in Patients with Metastatic Hormone-refractory Prostate Cancer
Clin. Cancer Res., December 1, 2001; 7(12): 3920 - 3927.
[Abstract] [Full Text] [PDF]


Home page
Mol. Biol. CellHome page
D. A. Flusberg, Y. Numaguchi, and D. E. Ingber
Cooperative Control of Akt Phosphorylation, bcl-2 Expression, and Apoptosis by Cytoskeletal Microfilaments and Microtubules in Capillary Endothelial Cells
Mol. Biol. Cell, October 1, 2001; 12(10): 3087 - 3094.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
X. A. Figueroa-Masot, M. Hetman, M. J. Higgins, N. Kokot, and Z. Xia
Taxol Induces Apoptosis in Cortical Neurons by a Mechanism Independent of Bcl-2 Phosphorylation
J. Neurosci., July 1, 2001; 21(13): 4657 - 4667.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
F. J. Esteva, V. Valero, L. Pusztai, L. Boehnke-Michaud, A. U. Buzdar, and G. N. Hortobagyi
Chemotherapy of Metastatic Breast Cancer: What to Expect in 2001 and Beyond
Oncologist, April 1, 2001; 6(2): 133 - 146.
[Abstract] [Full Text]


Home page
Am. J. Respir. Cell Mol. Bio.Home page
S. R. White, P. Williams, K. R. Wojcik, S. Sun, P. S. Hiemstra, K. F. Rabe, and D. R. Dorscheid
Initiation of Apoptosis by Actin Cytoskeletal Derangement in Human Airway Epithelial Cells
Am. J. Respir. Cell Mol. Biol., March 1, 2001; 24(3): 282 - 294.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
U. Vaishampayan, M. Glode, W. Du, A. Kraft, G. Hudes, J. Wright, and M. Hussain
Phase II Study of Dolastatin-10 in Patients with Hormone-refractory Metastatic Prostate Adenocarcinoma
Clin. Cancer Res., November 1, 2000; 6(11): 4205 - 4208.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. Zeng, Y. Z. Chen, L. Fu, K. R. Johnson, and W. Fan
In Vitro Evaluation of Schedule-dependent Interactions between Docetaxel and Doxorubicin against Human Breast and Ovarian Cancer Cells
Clin. Cancer Res., September 1, 2000; 6(9): 3766 - 3773.
[Abstract] [Full Text]


Home page
JCOHome page
C. F. Verschraegen, T. Sittisomwong, A. P. Kudelka, E. d. P. Guedes, M. Steger, T. Nelson-Taylor, M. Vincent, R. Rogers, E. N. Atkinson, and J. J. Kavanagh
Docetaxel for Patients With Paclitaxel-Resistant Mullerian Carcinoma
J. Clin. Oncol., July 14, 2000; 18(14): 2733 - 2739.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. V. Blagosklonny, P. C. Bishop, R. Robey, T. Fojo, and S. E. Bates
Loss of Cell Cycle Control Allows Selective Microtubule-active Drug-induced Bcl-2 Phosphorylation and Cytotoxicity in Autonomous Cancer Cells
Cancer Res., July 1, 2000; 60(13): 3425 - 3428.
[Abstract] [Full Text]


Home page
J. Immunol.Home page
C. Sgadari, E. Toschi, C. Palladino, G. Barillari, D. Carlei, A. Cereseto, C. Ciccolella, R. Yarchoan, P. Monini, M. Sturzl, et al.
Mechanism of Paclitaxel Activity in Kaposi's Sarcoma
J. Immunol., July 1, 2000; 165(1): 509 - 517.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
V. A. Miller, L. M. Krug, K. K. Ng, B. Pizzo, W. Perez, R. T. Heelan, and M. G. Kris
Phase II Trial of Docetaxel and Vinorelbine in Patients With Advanced Non-Small-Cell Lung Cancer
J. Clin. Oncol., March 13, 2000; 18(6): 1346 - 1350.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
H. Miayake, A. Tolcher, and M. E. Gleave
Chemosensitization and Delayed Androgen-Independent Recurrence of Prostate Cancer With the Use of Antisense Bcl-2 Oligodeoxynucleotides
J Natl Cancer Inst, January 5, 2000; 92(1): 34 - 41.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
R. Hopfner, M. Mousli, J.-M. Jeltsch, A. Voulgaris, Y. Lutz, C. Marin, J.-P. Bellocq, P. Oudet, and C. Bronner
ICBP90, a Novel Human CCAAT Binding Protein, Involved in the Regulation of Topoisomerase II{{alpha}} Expression
Cancer Res., January 1, 2000; 60(1): 121 - 128.
[Abstract] [Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
E. Chamoux
Involvement of the Angiotensin II Type 2 Receptor in Apoptosis during Human Fetal Adrenal Gland Development
J. Clin. Endocrinol. Metab., December 1, 1999; 84(12): 4722 - 4730.
[Abstract] [Full Text]


Home page
FASEB J.Home page
B. FADEEL, B. ZHIVOTOVSKY, and S. ORRENIUS
All along the watchtower: on the regulation of apoptosis regulators
FASEB J, October 1, 1999; 13(13): 1647 - 1657.
[Abstract] [Full Text]